Computational Studies and Synthesis of New Michael Acceptors for Drug Discovery Against COVID-19.
SARS-CoV-2; COVID-19; estratégia SBVS; Aceptores de Michael
The infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) initiates when the viral spike glycoprotein binds to angiotensin-converting enzyme 2 (ACE2) present on the membranes of human cells. This interaction is facilitated by the presence of the catalytic enzyme serine protease transmembrane 2 (TMPRSS2), which plays a crucial role in the virus's dissemination and pathogenicity. Studies have demonstrated that certain repurposed drugs can inhibit TMPRSS2, blocking the entry of SARS-CoV-2 into human host cells. However, these drugs exhibit adverse effects and a tendency to interact with various pharmacological targets, limiting their effectiveness in treating COVID-19. Thus, the aim of this study is to identify new compounds that act as Michael acceptors against TMPRSS2. To achieve this, virtual screening based on the receptor's structure (SBVS) and molecular dynamics studies were employed. The best screened molecules are undergoing chemical synthesis. Finally, these molecules are expected to be evaluated in biological assays against TMPRSS2 in the future.